RecruitingPhase 1NCT04972942
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- New York Medical College
- Principal Investigator
- Mitchell Cairo, MDNew York Medical College
- Intervention
- Daratumumab(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 39 years · All sexes
- Timeline
- 2023 – 2028
Study locations (16)
- Phoenix Children's Hospital, Phoeniz, Arizona, United States
- Loma Linda University Children's Hospital, Loma Linda, California, United States
- University of California, Los Angeles, California, United States
- University of California, San Francisco, California, United States
- Children's Hospital Colordao, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Florida, Gainsville, Florida, United States
- John Hopkins All Children's Hospital, St. Petersburg, Florida, United States
- Riley Children's Hospital, Indianapolis, Indiana, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
- New York Medical College, Vallhala, New York, United States
- Nationwide Children's Hosptial, Columbus, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04972942 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07201974Virtual Reality for Post-Stroke Gait RehabilitationMcGill University
- ENROLLING BY INVITATIONNCT07515430The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic LeukemiaSun Yat-sen University